Department of Gastroenterology, Sendai City Medical Center, Japan.
Intern Med. 2023 Mar 1;62(5):673-679. doi: 10.2169/internalmedicine.9370-22. Epub 2022 Jul 22.
Objective The present study evaluated the strategic role of percutaneous transhepatic gallbladder aspiration (PTGBA) for acute cholecystitis (AC) induced by a metallic stent (MS) placed in a malignant biliary stricture in comparison with percutaneous transhepatic gallbladder drainage (PTGBD). Methods The treatment outcomes for 31 patients who underwent PTGBA as the initial intervention for MS-induced AC were evaluated and compared with those for 12 who underwent PTGBD. Results The technical success rate was 100% for both groups. PTGBA was ineffective for 11 patients, all of whom recovered with additional intervention, whereas PTGBD was effective for all patients except for 1 who died of sepsis (clinical success rate, 65% vs. 90%, p=0.16). Adverse events (AEs) were observed in only 1 case (3%) in the PTGBA group (mild bile peritonitis). Among the clinically effective cases, AC recurred in 20% of the PTGBA group and 33% of the PTGBD group (p=0.72). In the PTGBA group, the clinical success rate was significantly higher for patients without cancer invasion to a feeding artery of the gallbladder than in those with invasion (75% without invasion vs. 29% with invasion; p=0.036). According to the multivariate analysis, this factor was an independent factor for clinical success of PTGBA (odds ratio, 9.27; p=0.040). Conclusion Although the clinical success rate of PTGBA for MS-induced AC was lower than that of PTGBD, PTGBA remains a viable option because of its safety and procedural simplicity, especially for cases without tumor invasion to a feeding artery.
本研究评估了经皮经肝胆囊穿刺抽吸术(PTGBA)在经金属支架(MS)置入治疗恶性胆道狭窄所致急性胆囊炎(AC)中的策略作用,并与经皮经肝胆囊引流术(PTGBD)进行了比较。
评估并比较了 31 例行 PTGBA 作为 MS 诱导的 AC 初始干预的患者的治疗结果,与 12 例行 PTGBD 的患者进行比较。
两组的技术成功率均为 100%。PTGBA 对 11 例患者无效,所有患者均通过额外干预治愈,而 PTGBD 对所有患者均有效,除 1 例因脓毒症死亡外(临床成功率,65% vs. 90%,p=0.16)。仅在 PTGBA 组观察到 1 例(3%)不良事件(AE)(轻度胆汁性腹膜炎)。在临床有效的病例中,PTGBA 组和 PTGBD 组 AC 复发率分别为 20%和 33%(p=0.72)。在 PTGBA 组中,胆囊供血动脉无肿瘤侵犯患者的临床成功率明显高于有侵犯的患者(75%无侵犯 vs. 29%有侵犯;p=0.036)。多因素分析显示,该因素是 PTGBA 临床成功的独立因素(比值比,9.27;p=0.040)。
虽然 PTGBA 治疗 MS 诱导的 AC 的临床成功率低于 PTGBD,但由于其安全性和操作简单性,PTGBA 仍然是一种可行的选择,特别是对于无肿瘤侵犯胆囊供血动脉的病例。